• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

New Hope for Parkinson’s: Cough Syrup Slows Cognitive Decline and Dementia

Raja Aditya by Raja Aditya
1 year ago
in Healthcare & Medicine, Science News
0
Parkinson

New Hope for Parkinson’s: Cough Syrup Slows Cognitive Decline and Dementia | Neo Science Hub

A recent phase 2 clinical trials has revealed promising findings regarding a common cough medicine, Ambroxol, which appears to stabilize psychiatric symptoms and potentially slow cognitive decline in patients suffering from Parkinson’s disease dementia (PDD). This innovative study, conducted by the Lawson Research Institute, involved 55 participants with PDD and lasted 12 months. The results indicated that Ambroxol, traditionally used as an expectorant to treat coughs, may also have neuroprotective qualities. Participants taking Ambroxol showed stabilization in their neuropsychiatric symptoms, while those receiving a placebo experienced a noticeable worsening of their conditions.

Parkinson’s disease, a progressive neurodegenerative disorder affecting movement, is characterized not only by motor symptoms such as tremors and stiffness but also by cognitive decline. Research shows that nearly half of individuals with Parkinson’s disease develop dementia within a decade of diagnosis, displaying symptoms that range from memory issues to mood disturbances. The study of Ambroxol highlights a potential new avenue for treatment in this area, particularly for genetically at-risk individuals possessing GBA1 risk variants.

The study’s outcomes demonstrated not just symptom stabilization, but also a protective effect against neuronal damage, as indicated by levels of serum GFAP, a known biomarker for brain injury. While the placebo group showed an increase in GFAP, indicating worsening brain health, those taking Ambroxol experienced no such increase. Additionally, some participants with genetic variants showed improved cognitive assessments, suggesting that Ambroxol’s ability to enhance glucocerebrosidase (GCase) activity—a key enzyme linked to the accumulation of alpha-synuclein in the brain—may play a significant role in alleviating cognitive decline.

Despite these promising findings, the study does have limitations, primarily due to the small sample size and the demographic diversity of participants. Consequently, further large-scale phase 3 trials are planned to confirm these results and evaluate the efficacy of Ambroxol in treating PDD more broadly. A significant benefit of this research is the potential for repurposing existing medications like Ambroxol to address complex neurodegenerative diseases, highlighting a cost-effective and readily available treatment option.

This study underlines the growing interest in using medications that serve dual purposes; those that were originally formulated for one condition might fulfil important roles in treating neurological disorders, opening pathways for precision medicine approaches that cater specifically to the genetic profiles of patients. The prospect of utilizing Ambroxol as a therapeutic agent for Parkinson’s dementia could pave the way for personalized treatment strategies, ultimately improving outcomes for patients grappling with these challenging conditions.

-Raja Aditya

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: AmbroxoldementiafeaturedhealthcarehealthscienceParkinson’s disease dementia (PDD)researchsciencenews
Raja Aditya

Raja Aditya

Associate Editor for Neo Science Hub Magazine

Other Posts

Young maize in paired rows on raised beds with water in the furrows between them

Lifting the Crop Off the Floor: Why Raised Beds Are Gaining Ground in a Water-Short Country

November 15, 2026
0
Trays of green and purple microgreens beside a field being sprayed

Small Leaves, Small Particles: Microgreens Have the Evidence. Nano-Urea Is Still Earning It

November 15, 2026
2

A Crore and a Half Recharge Pits Later: What India’s Water Reforms Can, and Cannot, Teach the Global South

A Purple Broccoli That Seeds in Delhi and a Sponge Gourd That Shrugs Off a Virus

Fourteen Seconds to 241 km/h and Back: What a Runway Test Says About Where Car Performance Now Lives

An Aeroplane on a Helipad: What Electra’s Manhattan Landing Proves, and What It Does Not

After the Space Station: NASA Opens the Contest to Become a Tenant in Orbit

At 94, the Air Force Counts Its Squadrons, and Waits for an Engine India Can Call Its Own

Next Post
Novartis

Novartis Secures Approval for Breakthrough Malaria Treatment for Infants

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
6

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist